Overview

Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH Patients Who Have an Inadequate Response to Eculizumab

Status:
Completed
Trial end date:
2018-03-28
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the safety and efficacy of RA101495 in patients with paroxysmal nocturnal hemoglobinuria (PNH) who have an inadequate response to eculizumab. Patients will be treated with RA101495 for 12 weeks.
Phase:
Phase 2
Details
Lead Sponsor:
Ra Pharmaceuticals